Using RNA editing to create new cancer targets for immunotherapy
Inducing Tumor Neoantigens Through RNA Editing for Cancer Immunotherapy
This study is looking at a new way to help your immune system recognize and fight tumors that usually don't respond well to current treatments, by making them more visible to your body's defenses, which could lead to better results for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10893482 on NIH RePORTER |
What this research studies
This research investigates how RNA editing can induce the expression of neoantigens in tumors, particularly those that are typically resistant to current immunotherapies. By enhancing the visibility of these tumors to the immune system, the study aims to improve the effectiveness of immune checkpoint inhibitors, which are treatments that help the immune system recognize and attack cancer cells. The research will involve analyzing tumor cells and immune responses to understand how these induced neoantigens can lead to better patient outcomes. Patients may benefit from this innovative approach if it successfully increases immune response against their tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with immunologically cold tumors, such as certain types of breast cancer, that have low mutational burdens.
Not a fit: Patients with tumors that are already responsive to existing immunotherapies may not receive additional benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with tumors that are currently difficult to treat with existing immunotherapies.
How similar studies have performed: Other research has shown promising results using similar RNA editing approaches to enhance immune responses in cancer treatment.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Hubbell, Jeffrey a. — University of Chicago
- Study coordinator: Hubbell, Jeffrey a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.